Margin of Insight
← Free primer

Investment Memorandum · Preview

For informational purposes only. Not investment advice.

Teradyne Inc.

TER

UNFAVORABLE

June 1, 2026

Research Conclusion

Bearish-to-Neutral at $373. The AI-test thesis has materialized but the stock has re-rated 270% to $373 embedding bull-case margins, HBM gains, and a permanent 30x+ multiple unsupported by history. Blended fair value is $190–$245 (DCF $162, multiples $245); probability-weighted 24M target ~$237–$249 implies -33% to -37% downside. The thesis works; the price doesn't. Trim holdings or wait for $250–280 pullback.

Company Overview & Moat Assessment

Teradyne (NASDAQ: TER) is a duopolist in semiconductor automatic test equipment with ~40% global market share versus Advantest's ~42%. Semiconductor Test (~78% of revenue) tests SoCs, memory including HBM, and AI accelerators requiring 3–5x tester-hours versus smartphone chips. Also owns Universal Robots and MiR (Robotics, ~8% revenue) and Product Test (~12%). Debt-free with $2.0–2.2B net cash; generates 22–27% FCF margins through cycle.

▲ Bull Case

  • ◆AI-test demand sustains beyond FY2027 via post-Blackwell GPU generations and 10–15 custom AI ASIC programs, driving bull-case FY2028 Sem Test revenue to $6.5B versus base $5.2B.
  • ◆HBM share grab via Lemsys platform achieves 25–35% market share by FY2028, capturing $500–700M incremental revenue at Sem Test gross margins and closing gap with Advantest.
  • ◆Robotics inflection as PolyScope X accelerates UR to $700M+ revenue with 20% software attach, unlocking $1.5–2.5B SOTP value and transforming segment from drag to growth driver.

▼ Bear Case

  • ◆AI capex cliff if hyperscalers digest initial buildouts by 2H FY2026/FY2027, causing Sem Test orders to decelerate sharply with 25% revenue decline versus base and multiple compression to mid-teens.
  • ◆Advantest dominates memory test if Lemsys-based HBM platforms fail qualification at scale, leaving Advantest with 80%+ HBM share and eliminating $400M+ revenue opportunity.
  • ◆China export controls + UR erosion + Apple verticalization create a three-part squeeze: BIS expands ATE controls (-$300M), Chinese cobots continue UR share grab, and Apple produces connectivity chips in-house (-$100–150M).
Primary Debate on Wall Street

“The core debate is not whether AI-test is real (settled by Q1 FY2026) but whether TER deserves a 28–35x structural premium or should revert to historical 20–22x median after the AI cycle peaks. Current 38x fwd P/E on $9.78 FY27 consensus EPS suggests multiple discipline has relaxed. Secondary debate centers on HBM Lemsys contribution and pace; tertiary debate treats Robotics as afterthought despite potential SOTP unlock. The Street is split between a durable-moat AI-cycle narrative and traditional cyclical-peak-to-trough compression.”

Top Catalysts
  • ◆Q2 FY2026 earnings and H2 guidance (Jul–Aug 2026) — either direction, key for AI ramp credibility
  • ◆HBM4 platform qualification at Micron or SK Hynix (6–12 months) — bullish for Lemsys variant view
  • ◆Custom AI ASIC design-win disclosure for TPU/Trainium/Maia (12–18 months) — bullish for TAM expansion
  • ◆UR sequential growth confirmation (3–6 months) — bullish only if delivered
  • ◆Nvidia Rubin GPU volume ramp signal via TSMC (6–18 months) — bullish for AI-test durability
  • ◆BIS rulemaking on advanced ATE export controls (ongoing) — bearish if expanded to China
  • ◆Investor Day with refreshed long-term targets (12–18 months) — clarifies multiple sustainability
Top Risks
  • ◆AI-capex cliff and WFE down-cycle: high probability, -40 to -60% EPS impact
  • ◆Multiple compression from 32x to 22x: high probability, -30% price impact standalone
  • ◆Advantest HBM dominance eliminates Lemsys variant: medium-high probability, -8 to -12% EPS impact
  • ◆China export-control escalation: medium probability, -12 to -20% EPS impact
  • ◆UR structural erosion to Chinese cobot vendors: medium probability, -10 to -15% EPS impact
  • ◆Apple in-house connectivity-chip test production: low-medium probability, -7 to -10% EPS impact
  • ◆CEO succession without named replacement: low probability, uncertain impact on strategy
  • ◆Taiwan supply-chain disruption: low probability, -5 to -10% EPS impact from event

Full Memo Continues

5 more sections, locked

  • ●
    Valuation Range & DCF
    Base/bull/bear fair-value range, WACC, terminal growth, sensitivity to revenue + margin assumptions.
  • ●
    Risk/Reward Assessment
    Position-sizing framework with explicit upside/downside skew and entry conditions.
  • ●
    Management & Capital Allocation
    Multi-year capital-allocation track record, incentive alignment, and management readout.
  • ●
    Monitoring Framework
    What to watch each quarter — leading indicators and inflection signals tracked by the analyst.
  • ●
    Unresolved Questions
    Open analyst questions and follow-up research items — the depth signal.

For Agents — $2 per memo

Call the JSON API with a Stripe Shared Payment Token. No account, no signup — just pay and call.

GET /api/v1/research/TER/memo
Authorization: Bearer spt_...

Fund managers — coverage subscriptions launching soon. See marginofinsight.com.

Margin of Insight

For informational purposes only. Not investment advice.